2021, Vol. 4, Issue 4, Part B
to study the methylprednisolone effects during cardiac surgery
Author(s): B Nagarjuna and Akhila NC
Abstract: Introduction and Background: Heart surgeries, especially those requiring cardiopulmonary bypass (CPB), are associated with an increased risk of postoperative consequences include organ failure and longer recovery times due to inflammatory reactions. The anti-inflammatory corticosteroid methylprednisolone has been studied for its ability to reduce these reactions. The purpose of this research is to determine whether or not methylprednisolone is safe and effective in lowering inflammation after heart surgery and enhancing clinical outcomes.
Materials and Methods: A randomised controlled experiment was done with 120 adult patients undergoing elective heart surgery with cardiopulmonary bypass (CPB). This study was conducted at the department of Anaesthesia, Surabhi Institute of Medical Sciences, Siddipet-Husnabad, Mundrai, Telangana, India from November 2020 to October 2021. Participants were randomly assigned to two groups: a methylprednisolone group (n = 60), administered 30 mg/kg intravenous methylprednisolone preoperatively and intraoperatively, and a control group (n = 60), receiving a placebo. The primary outcomes encompassed inflammatory indicators and surgical complications. The secondary outcomes included the duration of ICU stay, time to extubation, and 30-day mortality rate. Data were analysed utilising suitable statistical procedures, with p < 0.05 deemed significant.
Results: Methylprednisolone markedly diminished inflammatory indicators, resulting in decreased CRP and IL-6 levels in the intervention group relative to the control group. Patients receiving methylprednisolone had reduced ICU durations and expedited extubation intervals. The occurrence of postoperative complications was reduced in the methylprednisolone group, especially regarding respiratory dysfunction. No substantial variations in 30-day mortality were seen between the groups.
Conclusion: The injection of methylprednisolone during heart surgery significantly diminishes inflammatory responses, lowers ICU duration, and enhances early recovery outcomes without elevating mortality risk. Methylprednisolone may serve as a beneficial adjuvant in the perioperative care of patients undergoing heart surgery.
DOI: 10.33545/26643766.2021.v4.i4b.536
Pages: 112-116 | Views: 41 | Downloads: 17
Download Full Article: Click Here

How to cite this article:
B Nagarjuna, Akhila NC. to study the methylprednisolone effects during cardiac surgery. Int J Med Anesthesiology 2021;4(4):112-116. DOI: 10.33545/26643766.2021.v4.i4b.536